Who Paid My Doc
A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
ClinicalTrials.gov NCT05383209
Research payments
$2,347,749
Through program year 2024, $2,347,749 in research payments was reported against A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR), across 70 payments, paid by EyePoint Pharmaceuticals US, Inc..
- Paid by
- EyePoint Pharmaceuticals US, Inc.
- ClinicalTrials.gov
- NCT05383209
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $904,927 | 34 |
| 2023 | Research | $1,339,469 | 31 |
| 2022 | Research | $103,354 | 5 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Gregory Fox Lenexa, KS Named on 3 payments
- Dana Deupree Clearwater, FL Named on 3 payments
- Alessandro Castellarin Santa Barbara, CA Named on 3 payments
- Philip Storey Austin, TX Named on 3 payments
- Veeral Sheth Oak Forest, IL Named on 3 payments
- Daniel Roth New Brunswick, NJ Named on 2 payments
- Payam Amini Pasadena, CA Named on 2 payments
- Patrick Higgins Bloomfield, NJ Named on 2 payments
- Joel Pearlman Sacramento, CA Named on 2 payments
- Richard Scartozzi Danbury, CT Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.